Login to Your Account



Other News To Note


Tuesday, July 19, 2011
Transcept Pharmaceuticals Inc., of Point Richmond, Calif., is eliminating approximately 45 percent of its work force as it looks to conserve cash following the receipt of its second complete response letter from the FDA for insomnia drug Intermezzo (zolpidem tartrate sublingual tablet).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription